Akebia Therapeutics Inc (AKBA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Akebia Therapeutics Inc

Healthcare (1079)

617-871-2098

245 FIRST STREET, CAMBRIDGE, MA

Prossima data di guadagno

Ultimi documenti SEC

AKBA's Discussions on Twitter

Compare AKBA vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AKBA Akebia Therapeutics Inc	1.32	343.37M	232.40M	-20.51M	60.04M	-0.0771
TAK Takeda Pharmaceutical Co Adr	17.10	55.69B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.855	43.77B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	35.01	36.19B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	77.28	32.25B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	517.71	26.29B	3.17B	1.29B	1.01B	27.09

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-04	Ripresa	H.C. Wainwright	Buy
2025-04-28	Iniziato	Leerink Partners	Outperform
2025-04-01	Iniziato	Jefferies	Buy
2023-11-29	Ripresa	BTIG Research	Buy
2023-08-28	Aggiornamento	H.C. Wainwright	Neutral → Buy
2023-05-31	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-03-31	Downgrade	H.C. Wainwright	Buy → Neutral
2022-03-31	Downgrade	Mizuho	Buy → Neutral
2022-03-31	Downgrade	Needham	Buy → Hold
2022-03-31	Downgrade	Piper Sandler	Overweight → Neutral
2021-03-08	Iniziato	Cantor Fitzgerald	Overweight
2021-01-29	Downgrade	JP Morgan	Neutral → Underweight
2019-11-14	Reiterato	Needham	Buy
2019-08-06	Reiterato	H.C. Wainwright	Buy
2019-07-11	Reiterato	H.C. Wainwright	Buy
2019-05-02	Iniziato	JP Morgan	Overweight
2019-03-20	Iniziato	Citigroup	Neutral
2018-09-07	Ripresa	Morgan Stanley	Equal-Weight
2018-08-10	Reiterato	Needham	Buy
2018-06-06	Reiterato	H.C. Wainwright	Buy
2017-12-19	Iniziato	Piper Jaffray	Overweight
2017-12-07	Iniziato	BTIG Research	Buy
2017-09-15	Iniziato	RBC Capital Mkts	Sector Perform
2017-07-10	Reiterato	H.C. Wainwright	Buy
2017-04-27	Reiterato	H.C. Wainwright	Buy
2017-04-27	Reiterato	Needham	Buy
2016-12-27	Reiterato	H.C. Wainwright	Buy
2016-12-20	Reiterato	JMP Securities	Mkt Outperform
2016-11-15	Iniziato	Aegis Capital	Buy
2016-09-29	Iniziato	Brean Capital	Buy
2016-03-16	Reiterato	Needham	Buy
2016-01-21	Iniziato	Credit Suisse	Neutral

Mostra tutto

Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie

Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari

Akebia Therapeutics Inc (AKBA)

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Compare AKBA vs TAK, HLN, TEVA, ZTS, UTHR

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie

Akebia Therapeutics Inc (AKBA) Income Statement - TradingKey

Akebia Therapeutics Inc (AKBA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Akebia Therapeutics Inc (AKBA) Balance Sheet - TradingKey

Akebia Therapeutics Inc (AKBA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Akebia Therapeutics Inc (AKBA) Cash Flow - TradingKey

AKBA|Akebia Therapeutics Inc|Price:1.220| - TradingKey

Akebia Therapeutics Inc (AKBA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Akebia Therapeutics Inc (AKBA) Institutional Confidence - TradingKey

AKBA|Akebia Therapeutics Inc|Price:1.290|Chg%:+0.070 - TradingKey

AKBA|Akebia Therapeutics Inc|Price:1.280| - TradingKey

Akebia Therapeutics Inc (AKBA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Akebia Therapeutics, Inc. Revenue Breakdown – SWB:AX9 - TradingView

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Brokerages - MarketBeat

Akebia Therapeutics Inc (AKBA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Akebia Therapeutics (AKBA) Q2 2024 earnings summary - Quartr

Lobbying Update: $360,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative

Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Declines By 34.3% - MarketBeat

Akebia Therapeutics (NASDAQ:AKBA) Shares Pass Above Fifty Day Moving AverageHere's What Happened - MarketBeat

Lobbying Update: $60,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative

Akebia: Vafseo Gains Traction, But It’s Still A Show-Me Story (Rating Downgrade) (AKBA) - Seeking Alpha

ETFs Investing in Akebia Therapeutics, Inc. Stocks - TradingView

Akebia Therapeutics (AKBA) Jefferies Global Healthcare Conference 2026 Summary - Quartr

Akebia Therapeutics (AKBA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr

Akebia Therapeutics Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesPre-Earnings Setup - DonanımHaber

Zacks Research Upgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold - MarketBeat

Akebia Therapeutics (AKBA) Proxy filing Summary - Quartr

Akebia Therapeutics (AKBA) Climbs 5.38% as Stock Nears Key Resistance ZoneWeak Sell Signals - dars.gov.et

AKBAAkebia Therapeutics Inc Options - Finviz

Chief Business Officer Erik Ostrowski Sold A Bunch Of Shares In Akebia Therapeutics - Moomoo

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

AKBA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $6.00 - GuruFocus

Akebia Therapeutics Fortifies Vafseo Patent Protection Through 2036, Strengthening Commercial ProspectsProduct Revenue Analysis - dars.gov.et

Akebia Therapeutics (AKBA) CFO sells 56K shares in tax sell-to-cover - Stock Titan

H.C. Wainwright reiterates Akebia stock rating on trial results By Investing.com - Investing.com Canada

H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Akebia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Ostrowski Erik - Moomoo

Akebia TherapeuticsVoice Trial Meets Stopp - Moomoo

U.S. Renal Care and Akebia Therapeutics, Inc. Announce Interim Analysis of VOICE Trial Demonstrates Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo Versus ESA - marketscreener.com

Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036 - Yahoo Finance

Akebia (AKBA) VOICE Trial Halted Following Positive Interim Resu - GuruFocus

Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis - marketscreener.com

Akebia: VOICE trial stopped early after vadadustat shows superiority on primary composite endpoint - TradingView

Vafseo shows safer composite outcomes vs ESA in Akebia (AKBA) VOICE trial - Stock Titan

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA - marketscreener.com

Vafseo trial stops early after safety win in dialysis patients - Stock Titan

Form 144 Akebia Therapeutics For: 29 June By Investing.com - Investing.com Australia

Akebia Therapeutics (AKBA) lists 56,019 shares after RSU vesting on 06/28/2026 - Stock Titan

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akebia Therap - The National Law Review

Akebia Therapeutics, Inc. (AKBA) Investigation: Bronstein, Gewirt - The National Law Review

12 Best Low-Priced Pharma Stocks to Buy Right Now - Insider Monkey

Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a AKBA